Abstract
INTRODUCTION: Indolent T-cell lymphoma of the gastrointestinal tract (ITCL-GI) is a rare primary T-cell lymphoma from the gastrointestinal (GI) tract, there has been no documented successful treatment at the present time. RESULTS: A CD4(+)/CD8(-) ITCL-GI with STAT3::JAK2 fusion was treated with Jakafi (Ruxolitinib), which resulted in significant clinical improvements. CONCLUSION: Next generation sequencing is highly recommended for any new diagnosis of CD4(+)/CD8(-) ITCL-GI in order to detect if STAT3::JAK2 can be found in order to treat the patient with JAK2 inhibitor such as Jakafi (Ruxolitinib). CLINICAL TRIAL REGISTRATION: The authors have confirmed clinical trial registration is not needed for this submission.